Cantor Fitzgerald Comments on CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Perspective Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($0.90) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.09) EPS.

CATX has been the subject of a number of other research reports. Oppenheimer dropped their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $15.14.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $2.53 on Thursday. Perspective Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.05. The firm has a fifty day moving average price of $3.23 and a 200-day moving average price of $7.87.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after acquiring an additional 298,778 shares in the last quarter. WealthPlan Investment Management LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $4,530,000. State Street Corp raised its stake in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Janus Henderson Group PLC increased its stake in Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after acquiring an additional 355,685 shares during the last quarter. Finally, FMR LLC grew its stake in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.